Search Results

There are 5773 results for: content related to: Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis

  1. You have free access to this content
    Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

    British Journal of Haematology

    Volume 154, Issue 3, August 2011, Pages: 325–336, Antonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, Derek Mendy, Svetlana Gaidarova, Helen Brady, Justin Blake Bartlett, Peter H. Schafer, Martin Schreder, Arnold Bolomsky, Bernadette Hilgarth, Niklas Zojer, Heinz Gisslinger, Heinz Ludwig, Tom Daniel, Ulrich Jäger and Rajesh Chopra

    Version of Record online : 24 JUN 2011, DOI: 10.1111/j.1365-2141.2011.08689.x

  2. You have free access to this content
    Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients

    Clinical & Experimental Immunology

    Volume 177, Issue 2, August 2014, Pages: 439–453, A. Busch, D. Zeh, V. Janzen, L.-O. Mügge, D. Wolf, L. Fingerhut, C. Hahn-Ast, O. Maurer, P. Brossart and M. von Lilienfeld-Toal

    Version of Record online : 9 JUL 2014, DOI: 10.1111/cei.12343

  3. You have free access to this content
    Lenalidomide in multiple myeloma: Current status and future potential

    American Journal of Hematology

    Volume 87, Issue 12, December 2012, Pages: 1089–1095, Hang Quach, Anna Kalff and Andrew Spencer

    Version of Record online : 28 MAY 2012, DOI: 10.1002/ajh.23234

  4. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

    The Prostate

    Volume 72, Issue 8, 1 June 2012, Pages: 856–867, J.Y. Henry, L. Lu, M. Adams, B. Meyer, J.B. Bartlett, Prof. A.G. Dalgleish and C. Galustian

    Version of Record online : 3 OCT 2011, DOI: 10.1002/pros.21488

  5. You have free access to this content
    Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

    British Journal of Haematology

    Volume 160, Issue 4, February 2013, Pages: 487–502, Ling-Hua Zhang, Jolanta Kosek, Maria Wang, Carla Heise, Peter H. Schafer and Rajesh Chopra

    Version of Record online : 18 DEC 2012, DOI: 10.1111/bjh.12172

  6. You have free access to this content
    Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology

    Volume 166, Issue 2, July 2014, Pages: 189–201, Joaquín Sánchez-García, Consuelo del Cañizo, Ignacio Lorenzo, Benet Nomdedeu, Elisa Luño, Raquel de Paz, Blanca Xicoy, David Valcárcel, Salut Brunet, Victor Marco-Betes, Marta García-Pintos, Santiago Osorio, Mar Tormo, Alicia Bailén, Carlos Cerveró, Fernando Ramos, María Diez-Campelo, Esperanza Such, Beatriz Arrizabalaga, Gemma Azaceta, Joan Bargay, María J. Arilla, José Falantes, Josefina Serrano-López, Guillermo F. Sanz and forthe Spanish Group on Myelodysplastic Syndromes (GES MD)

    Version of Record online : 9 APR 2014, DOI: 10.1111/bjh.12876

  7. You have free access to this content
    Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: E60–E65, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Despina Kalapanida, Constantinos Pamboucas, Elisavet Kaldara, Argyrios Ntalianis, Erasmia Psimenou, Savvas T. Toumanidis, Anna Tasidou, Evangelos Terpos and Meletios A. Dimopoulos

    Version of Record online : 9 MAR 2015, DOI: 10.1002/ajh.23936

  8. You have free access to this content
    Short-Term Lenalidomide (Revlimid) Administration Ameliorates Cardiomyocyte Contractile Dysfunction in ob/ob Obese Mice


    Volume 20, Issue 11, November 2012, Pages: 2174–2185, Linlin Li, Yinan Hua, Maolong Dong, Quan Li, Derek T. Smith, Ming Yuan, Kyla R. Jones and Jun Ren

    Version of Record online : 31 DEC 2012, DOI: 10.1038/oby.2012.106

  9. Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis

    The Journal of Clinical Pharmacology

    Volume 47, Issue 12, December 2007, Pages: 1466–1475, Nianhang Chen, Henry Lau, Linghui Kong, Gondi Kumar, Jerom B. Zeldis, Robert Knight and Osca L. Laskin

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007309563

  10. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels

    European Journal of Haematology

    Volume 91, Issue 6, December 2013, Pages: 504–513, Alexandra J. Greenberg, Denise K. Walters, Shaji K. Kumar, S. Vincent Rajkumar and Diane F. Jelinek

    Version of Record online : 17 SEP 2013, DOI: 10.1111/ejh.12192

  11. You have free access to this content
    Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 327–333, Kami Maddocks, Lai Wei, Darlene Rozewski, Yao Jiang, Yuan Zhao, Mikhil Adusumilli, William E. Pierceall, Camille Doykin, Michael H. Cardone, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Michael R. Grever, John C. Byrd, Amy J. Johnson, Mitch A. Phelps and Kristie A Blum

    Version of Record online : 25 FEB 2015, DOI: 10.1002/ajh.23946

  12. Lenalidomide is safe and active in Waldenström macroglobulinemia

    American Journal of Hematology

    Volume 90, Issue 11, November 2015, Pages: 1055–1059, Guillemette Fouquet, Stéphanie Guidez, Marie-Odile Petillon, Chanaz Louni, Bella Ohyba, Malek Dib, Stéphanie Poulain, Charles Herbaux, Audrey Martin, Béatrice Thielemans, Pauline Brice, Sylvain Choquet, Jana Bakala, Claire Bories, Hélène Demarquette, Morgane Nudel, Olivier Tournilhac, Bertrand Arnulf, Steven LeGouill, Pierre Morel, Anne Banos, Lionel Karlin, Gilles Salles, Véronique Leblond and Xavier Leleu

    Version of Record online : 6 OCT 2015, DOI: 10.1002/ajh.24175

  13. You have free access to this content
    Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

    British Journal of Haematology

    Volume 155, Issue 4, November 2011, Pages: 457–467, Asher A. Chanan-Khan, Kasyapa Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry L. Mashtare Jr, Greg Wilding, Kelvin Lee, Myron S. Czuczman, Ivan Borrello and Naveen Bangia

    Version of Record online : 20 OCT 2011, DOI: 10.1111/j.1365-2141.2011.08882.x

  14. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer

    The Prostate

    Volume 72, Issue 5, April 2012, Pages: 487–498, Daniel J. Zabransky, Heath A. Smith, Christopher J. Thoburn, Marianna Zahurak, Daniel Keizman, Michael Carducci, Mario A. Eisenberger, Douglas G. McNeel, Charles G. Drake and Emmanuel S. Antonarakis

    Version of Record online : 11 JUL 2011, DOI: 10.1002/pros.21449

  15. Evaluation of the developmental toxicity of lenalidomide in rabbits

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 80, Issue 3, June 2007, Pages: 188–207, Mildred S. Christian, Oscar L. Laskin, Valerie Sharper, Alan Hoberman, David I. Stirling and Louise Latriano

    Version of Record online : 14 JUN 2007, DOI: 10.1002/bdrb.20115

  16. Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses

    The Journal of Clinical Pharmacology

    Volume 50, Issue 7, July 2010, Pages: 767–774, Nianhang Chen, Henry Lau, Somesh Choudhury, Xiaomin Wang, Mahmoud Assaf and Oscar L. Laskin

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009355157

  17. You have free access to this content
    Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: Results of a retrospective case review

    American Journal of Hematology

    Volume 86, Issue 6, June 2011, Pages: 467–470, M. Kathleen Figaro, Warren Clayton Jr., Chinenye Usoh, Kara Brown, Adetola Kassim, Vipul T. Lakhani and Shubhada Jagasia

    Version of Record online : 4 MAY 2011, DOI: 10.1002/ajh.22008

  18. You have full text access to this OnlineOpen article
    Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide

    Cancer Medicine

    Volume 5, Issue 7, July 2016, Pages: 1694–1701, Dana E. Rollison, Kenneth H. Shain, Ji-Hyun Lee, Shalaka S. Hampras, William Fulp, Kate Fisher, Najla H. Al Ali, Eric Padron, Jeffrey Lancet, Qiang Xu, Martha Olesnyckyj, Laurie Kenvin, Robert Knight, William Dalton, Alan List and Rami S. Komrokji

    Version of Record online : 20 APR 2016, DOI: 10.1002/cam4.721

  19. A review of the history, properties, and use of the immunomodulatory compound lenalidomide

    Annals of the New York Academy of Sciences

    Volume 1222, Issue 1, March 2011, Pages: 76–82, Jerome B. Zeldis, Robert Knight, Mohamad Hussein, Rajesh Chopra and George Muller

    Version of Record online : 22 MAR 2011, DOI: 10.1111/j.1749-6632.2011.05974.x

  20. You have free access to this content
    Lenalidomide performance in the real world


    Volume 119, Issue 21, 1 November 2013, Pages: 3870–3878, Amer M. Zeidan, Steven D. Gore, Diane L. McNally, Maria R. Baer, Franklin Hendrick, Dalia Mahmoud and Amy J. Davidoff

    Version of Record online : 6 AUG 2013, DOI: 10.1002/cncr.28298